Genprex Secures Key Global Patents for REQORSA Therapy

Genprex ( (GNPX) ) just unveiled an update.

On February 23, 2026, Genprex announced that the Japanese Patent Office issued a favorable appeal decision to grant a patent covering the use of REQORSA Gene Therapy with PD-L1 antibodies to treat cancer, while the European Patent Office granted a patent for REQORSA in combination with PD-1 antibodies. These new rights, to which Genprex holds exclusive licenses, add to existing patents in the U.S., Korea and multiple other countries, reinforcing protection for REQORSA-based combinations and bolstering the company’s global intellectual property position for its lead oncology asset.

The company highlighted that these patents underpin its Acclaim-3 Phase 1/2 trial in extensive-stage small cell lung cancer, which evaluates REQORSA with Genentech’s Tecentriq as maintenance therapy following standard-of-care treatment. Following a Phase 1 dose-escalation stage that found REQORSA generally well tolerated with no dose-limiting toxicities, the Phase 2 expansion aims to enroll about 50 patients, with an interim analysis planned after the 25th patient reaches 18 weeks of follow-up in 2026 under FDA Fast Track and Orphan Drug designations for the program.

More about Genprex

Genprex, Inc. is a clinical-stage oncology company developing gene therapies for cancer, with its lead drug candidate REQORSA® Gene Therapy focused on combination treatments for lung cancer. The company’s strategy centers on building a broad global intellectual property portfolio for REQORSA in key markets, particularly around its use with immune checkpoint inhibitors such as PD-1 and PD-L1 antibodies.

Average Trading Volume: 722,968

Technical Sentiment Signal: Sell

Current Market Cap: $4.31M

See more insights into GNPX stock on TipRanks’ Stock Analysis page.